Answers are grounded in this paper and cite their sources.
Since 2015, 69 countries and territories have reported evidence of vector-borne Zika virus (ZIKV) transmission. Currently, there are no effective licensed vaccines or drugs available for the treatment or prevention of ZIKV infection. We tested a series of compounds for their ability to inhibit ZIKV replication in cell culture. The compounds in T-705 (favipiravir) and T-1105 were found to have antiviral activity, suggesting that these compounds are promising candidates for further development as specific antiviral drugs against ZIKV.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: